Zsírmáj (MASLD/MASH): vizsgálatok itt: Puerto Rico
10 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleStudy to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- San Juan
- Életkor
- 18 év to 75 év
- People
- 360 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07631637 · EU 2026-525916-33-00 - 3. fázisTaking peopleA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Where
- Manati, Mayagüez, San Juan
- Életkor
- 18 év to 80 év
- People
- 1650 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06215716 - 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- San Juan
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- San Juan
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Manati, Mayagüez, San Juan
- Életkor
- 18 év to 80 év
- People
- 1350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Manati, Mayagüez, San Juan
- Életkor
- 18 év to 75 év
- People
- 1800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - 3. fázisTaking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Manati, Mayagüez, San Juan
- Életkor
- 18 év to 80 év
- People
- 2150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - 2. fázisTaking peopleA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Where
- Guaynabo, San Juan
- Életkor
- 18 év to 75 év
- People
- 120 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05519475 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Guaynabo, San Juan
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - 3. fázisTaking peopleA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- Where
- San Juan
- Életkor
- 18 év to 75 év
- People
- 1200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221227